

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal

Rimegepant for treating or preventing migraine [ID1539]

Final stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Biohaven Pharmaceuticals (rimegepant) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action on Pain • Brain and Spine Foundation • Brain Charity • Migraine Trust • National Migraine Centre • Neurological Alliance • OUCH UK • Pain Concern • Pain Relief Foundation • Pain UK • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of British Neurologists • British Association for the Study of Headache • British Geriatrics Society • British Neuropathological Society • British Pain Society • Health Lumen • Institute of Neurology • Migraine in Primary Care Advisors • Neuromodulation Society of UK and Ireland • Physiotherapy Pain Association • Primary Care and Community Neurology Society • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • Neurological Alliance of Scotland • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Wales Neurological Alliance • Welsh Health Specialised Services Committee <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (amitriptyline, almotriptan, aspirin, diclofenac, metoclopramide, paracetamol, prochlorperazine, propranolol, rizatriptan, sumatriptan, topiramate, zolmitriptan) • Advanz Pharma (metoclopramide, paracetamol) • Allergan (botulinum toxin type A) • Alliance Pharmaceuticals (aspirin, prochlorperazine) • Aspire Pharma (ibuprofen, paracetamol) • Aurobindo Pharma (domperidone, ibuprofen, paracetamol, propranolol, sumatriptan, topiramate)

Final stakeholder list for the single technology appraisal of rimegepant for treating or preventing migraine [ID1539]. Issue date: September 2021.

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Bristol, North Somerset, and South Gloucestershire CCG • NHS Dartford, Gravesham and Swanley CCG • NHS England • Welsh Government 	<ul style="list-style-type: none"> • Baxter Healthcare (paracetamol) • Boots (aspirin, ibuprofen, paracetamol, sumatriptan) • Bristol Laboratories (sumatriptan) • Bristol Myers Squibb Pharmaceuticals (paracetamol) • Brown and Burk UK (amitriptyline, prochlorperazine) • Cipla (paracetamol) • Dexcel-Pharma (sumatriptan) • Dr Reddy's Laboratories UK (aspirin, sumatriptan) • Eli Lilly (galcanezumab) • Fannin (paracetamol) • Flamingo Pharma UK (amitriptyline, ibuprofen, paracetamol) • Galderma (botulinum toxin type A) • Galen (paracetamol) • Genus Pharmaceuticals (zolmitriptan) • GlaxoSmithKline (aspirin, ibuprofen, paracetamol, sumatriptan) • Glenmark Pharmaceuticals (rizatriptan, topiramate, zolmitriptan) • Grunenthal (paracetamol, zolmitriptan) • Healthcare Pharma (aspirin, metoclopramide) • Infirst Healthcare (ibuprofen) • Intraparm Laboratories (paracetamol) • Ipca Laboratories (paracetamol) • Janssen-Cilag (topiramate) • Kent Pharmaceuticals (paracetamol) • M&A Pharmachem (aspirin, paracetamol) • Martindale Pharmaceuticals (aspirin) • McNeil Products (ibuprofen, paracetamol) • Merz Pharma (botulinum toxin type A) • Mylan (ibuprofen, rizatriptan, sumatriptan, topiramate, zolmitriptan) • Neuraxpharm UK (rizatriptan) • Novartis (erenumab) • Omega Pharma (ibuprofen, paracetamol) • Organon (rizatriptan) • Pfizer (ibuprofen, eletriptan) • Pinewood Healthcare (ibuprofen, paracetamol)

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> • Reckitt Benckisser Healthcare (paracetamol, aspirin, ibuprofen) • Rosemont Pharmaceuticals (amitriptyline, metoclopramide, paracetamol, propranolol, topiramate) • Sandoz (propranolol) • Sanofi (metoclopramide, paracetamol, prochlorperazine) • Sun Pharmaceuticals UK (sumatriptan) • Teva UK Limited (fremanezumab) • Thame Laboratories (amitriptyline, metoclopramide, propranolol) • Tillomed Laboratories (propranolol, rizatriptan) • Trion Pharma (paracetamol) • Typharm (paracetamol) • UCB Pharma (paracetamol) • Wockhardt UK (amitriptyline, ibuprofen) • Zentiva UK (aspirin, domperidone, metoclopramide, paracetamol) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Brain Research UK • British Neurological Research Trust • Cochrane Pain, Palliative Care and Supportive Care Group • Genomics England • MRC Clinical Trials Unit • National Hospital for Neurology and Neurosurgery • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.